BioXcel Therapeutics, Inc. (NASDAQ:BTAI)’s stock price hit a new 52-week low during trading on Friday . The company traded as low as $18.33 and last traded at $18.40, with a volume of 2824 shares. The stock had previously closed at $19.45.
A number of equities analysts have recently commented on the stock. HC Wainwright reissued a “buy” rating and issued a $141.00 price target on shares of BioXcel Therapeutics in a report on Tuesday, October 19th. The Goldman Sachs Group lowered shares of BioXcel Therapeutics from a “neutral” rating to a “sell” rating and decreased their price target for the stock from $55.00 to $24.00 in a report on Monday, November 15th. One research analyst has rated the stock with a sell rating and five have given a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $97.29.
The company’s fifty day moving average is $23.68 and its 200 day moving average is $26.75. The company has a market cap of $516.51 million, a P/E ratio of -4.49 and a beta of 0.97.
Several hedge funds have recently added to or reduced their stakes in the stock. FMR LLC grew its holdings in shares of BioXcel Therapeutics by 39.7% during the 2nd quarter. FMR LLC now owns 3,114,813 shares of the company’s stock valued at $90,516,000 after purchasing an additional 884,970 shares during the last quarter. State Street Corp grew its holdings in shares of BioXcel Therapeutics by 14.4% during the 2nd quarter. State Street Corp now owns 1,459,115 shares of the company’s stock valued at $42,402,000 after purchasing an additional 183,209 shares during the last quarter. BlackRock Inc. grew its holdings in shares of BioXcel Therapeutics by 7.4% during the 3rd quarter. BlackRock Inc. now owns 1,216,737 shares of the company’s stock valued at $36,928,000 after purchasing an additional 84,335 shares during the last quarter. Alliancebernstein L.P. boosted its position in BioXcel Therapeutics by 8.2% during the 3rd quarter. Alliancebernstein L.P. now owns 1,020,255 shares of the company’s stock valued at $30,965,000 after buying an additional 76,995 shares during the period. Finally, Vanguard Group Inc. boosted its position in BioXcel Therapeutics by 14.3% during the 2nd quarter. Vanguard Group Inc. now owns 902,646 shares of the company’s stock valued at $26,231,000 after buying an additional 113,207 shares during the period. 45.59% of the stock is currently owned by institutional investors.
BioXcel Therapeutics Company Profile (NASDAQ:BTAI)
BioXcel Therapeutics, Inc is a clinical stage biopharmaceutical company, which focuses on drug development. The firm’s two clinical development programs are BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer.
Recommended Story: Breakout Stocks
Receive News & Ratings for BioXcel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioXcel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.